


IN THE CLAIMS:

Claim 1 (currently amended): A compound of general formula




wherein

D represents CH₂ or CH₂CH₂;

E represents C(O)NH or NHC(O);

R¹ and R² each independently represent hydrogen, halogen, amino, nitro, C₁-C₆ alkyl or trifluoromethyl, but R¹ and R² may not both simultaneously represent hydrogen;

R³ represents a group of formula



R⁴ represents a C₁-C₆ alkyl group;

X represents a group NR¹³;

R⁵ represents hydrogen; and

R¹³ represents hydrogen, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkylmethyl, or R¹³ represents a C₁-C₆ alkyl group optionally substituted by at least one substituent selected from hydroxyl and C₁-C₆ alkoxy; and

with the proviso that when E is C(O)NH, X is not NH or N(C₁-C₆ alkyl);

or a pharmaceutically acceptable salt or solvate thereof.

Claim 2 (original): A compound according to claim 1, wherein D represents CH₂.

Claim 3 (**previously presented**): A compound according to claim 1, wherein E represents NHC(O).

Claim 4 (**previously presented**): A compound according to claim 1, wherein R¹ and R² each independently represent a hydrogen, chlorine or bromine atom, or an amino, nitro, C₁-C₃ alkyl or trifluoromethyl group.

Claim 5 (**cancelled**).

Claim 6 (**previously presented**): A compound according to claim 1, wherein X represents a group NR¹³ in which R¹³ represents hydrogen, -(CH₂)₂OH, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-pentyl, n-hexyl, cyclopropyl, cyclopentyl, cyclohexyl or cyclohexylmethyl.

Claims 7-9 (**cancelled**).

Claim 10 (**currently amended**): A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, according to claim 1 which is selected from:

2-Chloro-5-[(3-hydroxy-2,2-dimethylpropylamino)methyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[(5-hydroxypentylamino)methyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, acetate salt,

2-Chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,

2-Chloro-5-[3-(methylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, acetate salt,

- 2-Chloro-5-[3-[(1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- 2-Chloro-5-[3-[(4-hydroxybutyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,
- 2-Chloro-5-[3-[(2-hydroxy-2-methylpropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, acetate salt,
- (S)-2-Chloro-5-[3-[(2-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- (R)-2-Chloro-5-[3-[(2-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- (R)-2-Chloro-5-[3-[(2-hydroxy-1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- 2-Chloro-5-[3-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,
- 2-Chloro-5-[3-[(3-methoxypropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- 2-Chloro-5-[3-[(3-hydroxy-3-methylbutyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- 2-Chloro-5-[3-[(2-methoxyethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, hydrochloride salt,
- 5-(2-Aminoethyl)-2-chloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)benzamide,
- 2-Chloro-5-[3-(cyclohexylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,
- 2-Chloro-5-[3-[[1-(hydroxymethyl)-2,2-dimethylpropyl]amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,
- 2-Chloro-5-[3-(cyclopropylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,
- 2-Chloro-5-[3-[(3-hydroxy-2,2-dimethylpropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-[(1,1-dimethylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-(cyclopentylamino)propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-5-[3-[(1,2,2-trimethylpropyl)amino]propyl]-benzamide,

5-[3-(Butylamino)propyl]-2-chloro-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-[[1-(hydroxymethyl)-2-methylpropyl]amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-[(1-methylpropyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,


2-Chloro-5-[3-[(2-hydroxy-1,1-dimethylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide,

2-Chloro-5-[3-[(cyclohexylmethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide, and

2-Chloro-5-[3-[(2-methoxy-1-methylethyl)amino]propyl]-N-(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)-benzamide.


Claim 11 (**withdrawn**): A process for the preparation of a compound of formula (I) as defined in claim 1 which comprises:

(a) reacting a compound of general formula




(III)

wherein L^1 represents a leaving group and D, E, R^1 , R^2 and R^4 are as defined in formula (I), with a compound of general formula



wherein R^5 and R^{13} are as defined in formula (I), optionally in the presence of a suitable silver salt; or

(b) reacting a compound of general formula



wherein R^{20} represents a bond or C_1 - C_5 alkyl group and D, E, R^1 and R^2 are as defined in formula (I), with a compound of general formula (VI) as defined in (a) above, in the presence of a reducing agent;

and optionally after (a) or (b) converting the compound of formula (I) obtained to a pharmaceutically acceptable salt ~~or solvate~~ thereof.

Claim 12 (currently amended): A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt ~~or solvate~~ thereof, as claimed in any one of claims 1-4, 6 and 10 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claim 13 (**withdrawn**): A process for the preparation of a pharmaceutical composition as claimed in claim 12 which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt ~~or solvate~~ thereof, as defined in any one of claims 1-4, 6 and 10 with a pharmaceutically acceptable adjuvant, diluent or carrier.

Claims 14-19 (**cancelled**).

Claim 20 (**withdrawn**): A method of effecting immunosuppression which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt ~~or solvate~~ thereof, as claimed in any one of claims 1-4, 6 and 10 to a patient in need thereof.

Claim 21 (**withdrawn**): A method of treating rheumatoid arthritis which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt ~~or solvate~~ thereof, as claimed in any one of claims 1-4, 6 and 10 to a patient in need thereof.

Claim 22 (**withdrawn**): A method of treating chronic obstructive pulmonary disease which comprises administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt ~~or solvate~~ thereof, as claimed in any one of claims 1-4, 6 and 10 to a patient in need thereof.